Olema Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
OLMA$7.36+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(Amounts in thousands, except for share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $48,301 | $139,480 |
| Marketable securities | 457,136 | 294,606 |
| Prepaid expenses and other current assets | 10,015 | 4,387 |
| Total current assets | 515,452 | 438,473 |
| Operating lease right-of-use assets | 1,146 | 1,314 |
| Other assets and long-term deposits | 16,832 | 11,192 |
| Total assets | $533,430 | $450,979 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $9,253 | $4,460 |
| Operating lease liabilities, current | 1,124 | 1,172 |
| Other current liabilities (Note 6) | 41,425 | 36,126 |
| Total current liabilities | 51,802 | 41,758 |
| Operating lease liabilities, net of current portion | 69 | 257 |
| Long-term borrowing | 3,000 | — |
| Total liabilities | 54,871 | 42,015 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024. | — | — |
| Common stock, $0.0001 par value; 490,000,000 shares authorized as of December 31, 2025 and 2024; 81,376,449 and 74,312,608 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 8 | 7 |
| Additional paid-in capital | 1,075,487 | 843,920 |
| Accumulated other comprehensive income | 621 | 143 |
| Accumulated deficit | (597,557) | (435,106) |
| Total stockholders’ equity | $478,559 | $408,964 |
| Total liabilities and stockholders’ equity | $533,430 | $450,979 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.